MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
121 hedge funds and large institutions have $1.75B invested in MyoKardia, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 66 increasing their positions, 32 reducing their positions, and 21 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 32
19% more capital invested
Capital invested by funds: $1.47B → $1.75B (+$278M)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
10% more call options, than puts
Call options by funds: $4.04M | Put options by funds: $3.68M
5% less funds holding
Funds holding: 128 → 121 (-7)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$42.1M |
| 2 |
BlackRock
New York
|
+$39.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.7M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$43.2M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$33.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.96M |
| 4 |
Axa
Paris,
France
|
-$4.92M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$4.85M |
MYOK Hedge Fund Activity: Q2 2018 in Review
121 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q2 2018, worth a combined $1.75B — up 19% from $1.47B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of MYOK and 15 opened new positions — a net loss of 6 holders — while 32 trimmed existing stakes and 66 added.
The largest buyer was PFM Health Sciences, adding an estimated $42.1M. The largest seller was TRV GP II, exiting entirely with an estimated $43.2M sold.
- 121 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q2 2018, down from 128 in Q1 2018.
- Funds reported $1.75B of MyoKardia, Inc. Common Stock stock for Q2 2018, up 19% quarter-over-quarter.
- 15 funds opened new MyoKardia, Inc. Common Stock positions in Q2 2018 and 21 closed out, a net change of -6 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q2 2018 was PFM Health Sciences, an estimated $42.1M added.
- The largest MyoKardia, Inc. Common Stock seller in Q2 2018 was TRV GP II, an estimated $43.2M sold.
Based on aggregated 13F filings for Q2 2018.